{"id":"tetryzoline","rwe":[],"tags":[{"label":"tetryzoline","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Adrenergic receptor alpha","category":"target"},{"label":"ADRA1A","category":"gene"},{"label":"ADRA1B","category":"gene"},{"label":"ADRA1D","category":"gene"},{"label":"R01AA06","category":"atc"},{"label":"Ophthalmic","category":"route"},{"label":"Liquid","category":"form"},{"label":"Active","category":"status"},{"label":"Nasal congestion","category":"indication"},{"label":"Nasal discharge","category":"indication"},{"label":"Red eye","category":"indication"},{"label":"Fougera Pharms","category":"company"},{"label":"Approved 1970s","category":"decade"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Nasal Decongestants","category":"pharmacology"},{"label":"Ophthalmic Solutions","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Pharmaceutical Solutions","category":"pharmacology"},{"label":"Respiratory System Agents","category":"pharmacology"},{"label":"Sympathomimetics","category":"pharmacology"},{"label":"Vasoconstrictor Agents","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":17.9,"date":"","count":17,"signal":"Dry mouth","source":"DrugCentral FAERS","actionTaken":"Reported 17 times (LLR=18)"}],"commonSideEffects":[],"contraindications":["Diabetes mellitus","Disorder of cardiovascular system","Hyperthyroidism"]},"trials":[],"aliases":[],"company":"Fougera Pharms","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=tetryzoline","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:02:47.028874+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:02:53.528737+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=tetryzoline","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:02:54.921867+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1266/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:02:55.413058+00:00"}},"allNames":"ocuzolin","offLabel":[],"synonyms":["tetrahydrozoline nitrate","tetrahydrozoline","(+/-)-Tetrahydrozoline","ocuzolin","tetryzolin","tetryzoline","dl-Tetrahydrozoline","tetrahydrozoline hydrochloride","tetrahydrozeline hydrochloride","tetrahydrozeline nitrate","tetrahydrozoline HCl","tetrahydrozeline HCl"],"timeline":[{"date":"1979-11-30","type":"positive","source":"DrugCentral","milestone":"FDA approval (Fougera Pharms)"}],"approvals":[{"date":"1979-11-30","orphan":false,"company":"FOUGERA PHARMS","regulator":"FDA"}],"brandName":"Ocuzolin","ecosystem":[{"indication":"Nasal congestion","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"ammonium chloride","slug":"ammonium-chloride","company":"B Braun"},{"name":"antazoline","slug":"antazoline","company":"Novartis"}],"globalPrevalence":null},{"indication":"Nasal discharge","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"ammonium chloride","slug":"ammonium-chloride","company":"B Braun"},{"name":"antazoline","slug":"antazoline","company":"Novartis"}],"globalPrevalence":30000000},{"indication":"Red eye","otherDrugs":[{"name":"antazoline","slug":"antazoline","company":"Novartis"},{"name":"crospovidone","slug":"crospovidone","company":""},{"name":"macrogol","slug":"macrogol","company":"Braintree"},{"name":"naphazoline","slug":"naphazoline","company":"Novartis"}],"globalPrevalence":null}],"mechanism":{"target":"Adrenergic receptor alpha","novelty":"Follow-on","targets":[{"gene":"ADRA1A","source":"DrugCentral","target":"Adrenergic receptor alpha","protein":"Alpha-1A adrenergic receptor"},{"gene":"ADRA1B","source":"DrugCentral","target":"Adrenergic receptor alpha","protein":"Alpha-1B adrenergic receptor"},{"gene":"ADRA1D","source":"DrugCentral","target":"Adrenergic receptor alpha","protein":"Alpha-1D adrenergic receptor"},{"gene":"ADRA2A","source":"DrugCentral","target":"Adrenergic receptor alpha","protein":"Alpha-2A adrenergic receptor"},{"gene":"ADRA2B","source":"DrugCentral","target":"Adrenergic receptor alpha","protein":"Alpha-2B adrenergic receptor"},{"gene":"ADRA2C","source":"DrugCentral","target":"Adrenergic receptor alpha","protein":"Alpha-2C adrenergic receptor"}],"modality":"Small Molecule","drugClass":"tetryzoline","explanation":"","oneSentence":"","technicalDetail":"Ocuzolin acts as an agonist at the alpha-adrenergic receptor, triggering a cascade of downstream effects that ultimately lead to vasoconstriction and reduced nasal and ocular congestion."},"commercial":{"launchDate":"1979","_launchSource":"DrugCentral (FDA 1979-11-30, FOUGERA PHARMS)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3591","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=tetryzoline","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=tetryzoline","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:52:21.755802","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:02:57.475211+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"ephedrine","drugSlug":"ephedrine","fdaApproval":"","patentExpiry":"May 16, 2040","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"phenylephrine","drugSlug":"phenylephrine","fdaApproval":"1952-01-21","patentExpiry":"Sep 26, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"oxymetazoline","drugSlug":"oxymetazoline","fdaApproval":"1986-05-30","patentExpiry":"May 2, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"xylometazoline","drugSlug":"xylometazoline","fdaApproval":"","relationship":"same-class"},{"drugName":"naphazoline","drugSlug":"naphazoline","fdaApproval":"1971-06-07","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"epinephrine","drugSlug":"epinephrine","fdaApproval":"1948-11-19","patentExpiry":"Oct 20, 2036","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"tetryzoline","indications":{"approved":[{"name":"Nasal congestion","source":"DrugCentral","snomedId":68235000,"regulator":"FDA","eligibility":"children under 2 years of age: ask doctor"},{"name":"Nasal discharge","source":"DrugCentral","snomedId":64531003,"regulator":"FDA","eligibility":"children under 2 years of age: ask doctor","usPrevalence":null,"globalPrevalence":30000000,"prevalenceMethod":"curated","prevalenceSource":"Influenza Other Respir Viruses, 2023 (PMID:36824394)"},{"name":"Red eye","source":"DrugCentral","snomedId":75705005,"regulator":"FDA","eligibility":"children under 2 years of age: ask doctor"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"ephedrine","brandName":"ephedrine","genericName":"ephedrine","approvalYear":"","relationship":"same-class"},{"drugId":"phenylephrine","brandName":"phenylephrine","genericName":"phenylephrine","approvalYear":"1952","relationship":"same-class"},{"drugId":"oxymetazoline","brandName":"oxymetazoline","genericName":"oxymetazoline","approvalYear":"1986","relationship":"same-class"},{"drugId":"xylometazoline","brandName":"xylometazoline","genericName":"xylometazoline","approvalYear":"","relationship":"same-class"},{"drugId":"naphazoline","brandName":"naphazoline","genericName":"naphazoline","approvalYear":"1971","relationship":"same-class"},{"drugId":"epinephrine","brandName":"epinephrine","genericName":"epinephrine","approvalYear":"1948","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07457216","phase":"NA","title":"Visual and Patient-Reported Outcomes After Bilateral Non-Diffractive EDOF IOL Implantation","status":"COMPLETED","sponsor":"Benha University","startDate":"2025-01-03","conditions":["Extended Depth-of-Focus Intraocular Lens","Cataract","Visual Acuity"],"enrollment":30,"completionDate":"2025-01-31"},{"nctId":"NCT07436871","phase":"NA","title":"Comparison of Visual Outcomes and Patient Satisfaction in Mild to Moderate Glaucoma Patients Undergoing Cataract Surgery With EDOF Versus Monofocal IOLs","status":"NOT_YET_RECRUITING","sponsor":"OMIQ Research","startDate":"2026-01-31","conditions":["GLAUCOMA 1, OPEN ANGLE, D (Disorder)","Cataract"],"enrollment":74,"completionDate":"2027-02"},{"nctId":"NCT04440280","phase":"PHASE2","title":"Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy","status":"RECRUITING","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2020-09-16","conditions":["Fuchs Endothelial Corneal Dystrophy"],"enrollment":45,"completionDate":"2027-04-30"},{"nctId":"NCT06431841","phase":"PHASE4","title":"Atropine and Spectacle Combination Treatment (ASPECT): 12-month Results of a Randomized Clinical Trial for Myopia Control","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hospital San Carlos, Madrid","startDate":"2022-02-23","conditions":["Myopia"],"enrollment":111,"completionDate":"2026-06-30"},{"nctId":"NCT07088796","phase":"NA","title":"Toric Intraocular Lens Implantation for Pediatric Aphakia","status":"COMPLETED","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2017-10-07","conditions":["Pediatric Cataract","Congenital Cataract"],"enrollment":236,"completionDate":"2024-10-18"},{"nctId":"NCT06535932","phase":"NA","title":"Amara View Benchmark Study","status":"COMPLETED","sponsor":"Philips Clinical & Medical Affairs Global","startDate":"2024-07-25","conditions":["Sleep Apnea Syndromes"],"enrollment":35,"completionDate":"2024-09-06"},{"nctId":"NCT07067476","phase":"NA","title":"Instant Flush Redness Clinical Efficacy Study","status":"NOT_YET_RECRUITING","sponsor":"ChinaNorm","startDate":"2025-07-15","conditions":["Sensitive Skin"],"enrollment":60,"completionDate":"2025-10-31"},{"nctId":"NCT05848245","phase":"NA","title":"Reducing Aerosol and Bioaerosol Using Different Oral Suctions","status":"COMPLETED","sponsor":"King Abdulaziz University","startDate":"2023-05-01","conditions":["Infections","Oral Infection"],"enrollment":50,"completionDate":"2023-11-01"},{"nctId":"NCT06714994","phase":"NA","title":"Effect of Spectacle Distribution to Myopic Secondary School Students in Rural Communities of Liaoning Province on Communities Academic High School Enrolment","status":"NOT_YET_RECRUITING","sponsor":"He Eye Hospital","startDate":"2024-12-01","conditions":["Myopia"],"enrollment":1980,"completionDate":"2027-12-01"},{"nctId":"NCT06548308","phase":"NA","title":"Comparison of Corneal Incision Versus Toric Intraocular Lens Techniques Used in Cataract Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Superior University","startDate":"2020-10-01","conditions":["Cataract Surgery"],"enrollment":368,"completionDate":"2024-09-30"},{"nctId":"NCT05541796","phase":"NA","title":"Clinical Outcomes Following Implantation of Tecnis Synergy and Symfony Intraocular Lens","status":"COMPLETED","sponsor":"George O. Waring IV","startDate":"2022-09-19","conditions":["Cataract"],"enrollment":26,"completionDate":"2023-12-31"},{"nctId":"NCT03198000","phase":"PHASE3","title":"A Study to Evaluate the Efficacy of Investigational OTC Eye Drops","status":"COMPLETED","sponsor":"Johnson & Johnson Consumer Inc. (J&JCI)","startDate":"2017-06-28","conditions":["Ophthalmic Solutions"],"enrollment":120,"completionDate":"2017-07-21"},{"nctId":"NCT02656953","phase":"NA","title":"The Impact of Lenses on Musculoskeletal and Visual Complaints in VDU Workers With Neck Complaints","status":"COMPLETED","sponsor":"University Ghent","startDate":"2015-03","conditions":["Neck Pain"],"enrollment":40,"completionDate":"2016-05"},{"nctId":"NCT05326607","phase":"NA","title":"Pilot Clinical Investigation of Adaptative Eyeglasses for the Correction of Presbyopia","status":"COMPLETED","sponsor":"Laclaree","startDate":"2021-09-09","conditions":["Presbyopia"],"enrollment":40,"completionDate":"2022-01-27"},{"nctId":"NCT03286426","phase":"NA","title":"Ocular Screening in Children and Young Adults at Risk for Increased Intracranial Pressure","status":"TERMINATED","sponsor":"Duke University","startDate":"2017-10-26","conditions":["Intracranial Pressure Increase"],"enrollment":3,"completionDate":"2018-12-08"},{"nctId":"NCT05028907","phase":"PHASE4","title":"Evaluation of Lacrimal Punctal Changes by Anterior Segment Optical Coherence Tomography AS-OCT After Topical Combined Antibiotics and Steroids Treatment in Cases of Inflammatory Punctual Stenosis","status":"COMPLETED","sponsor":"Sohag University","startDate":"2020-11-15","conditions":["Ophthalmopathy , Lacrimal System"],"enrollment":64,"completionDate":"2021-07-15"},{"nctId":"NCT04362215","phase":"","title":"Heart Aging When Near Vision Difficulty Begins","status":"COMPLETED","sponsor":"Kecioren Education and Training Hospital","startDate":"2019-09-10","conditions":["Aging"],"enrollment":500,"completionDate":"2020-03-15"},{"nctId":"NCT03023488","phase":"NA","title":"Effects of Flexible Ureteroscopy on Renal Blood Flow","status":"COMPLETED","sponsor":"Marmara University","startDate":"2016-02","conditions":["Circulatory; Change"],"enrollment":46,"completionDate":"2016-12"},{"nctId":"NCT03228199","phase":"NA","title":"PROductivity Study of Presbyopia Elimination in Rural-dwellers (PROSPER)","status":"COMPLETED","sponsor":"Congdon Nathan","startDate":"2017-07-24","conditions":["Presbyopia"],"enrollment":751,"completionDate":"2017-10-28"},{"nctId":"NCT00347854","phase":"NA","title":"Fluorophotometry Evaluation of Lubricant Eye Drops","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2006-04","conditions":["Healthy"],"enrollment":40,"completionDate":"2006-04"},{"nctId":"NCT01970267","phase":"NA","title":"Clear Vision Study","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2013-10","conditions":["Posterior Vitreous Detachment","Vitreous Floaters"],"enrollment":35,"completionDate":"2016-02"},{"nctId":"NCT00591110","phase":"NA","title":"Project inCharge: Increasing the Rate of Comprehensive Eye Care Utilization by Older African Americans Through Community-Based Eye Health Education Program","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2008-06","conditions":["Eye Disease","Eye Care","Vision"],"enrollment":177,"completionDate":"2009-12"},{"nctId":"NCT01105624","phase":"PHASE4","title":"A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Rewetting Drops in Subjects With History and Current Complaint of Contact Lens-Related Dry Eye (CLDE)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-03","conditions":["Contact Lens Dry Eye"],"enrollment":50,"completionDate":"2010-11"},{"nctId":"NCT01380678","phase":"PHASE3","title":"Intralesional Bevacizumab Injection on Primary Pterygium","status":"UNKNOWN","sponsor":"Khon Kaen University","startDate":"2009-01","conditions":["Pterygium","Inflammation"],"enrollment":206,"completionDate":"2012-12"},{"nctId":"NCT01227226","phase":"PHASE4","title":"Tear Osmolarity Over Time With Artificial Tears","status":"UNKNOWN","sponsor":"Hom, Milton M., OD, FAAO","startDate":"2010-10","conditions":["Dry Eye"],"enrollment":48,"completionDate":"2011-03"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Ophthalmic","formulation":"Liquid","formulations":[{"form":"LIQUID","route":"OPHTHALMIC","productName":"Murine Plus 2"},{"form":"LIQUID","route":"OPHTHALMIC","productName":"Murine Tears Plus 3"},{"form":"LIQUID","route":"OPHTHALMIC","productName":"Clear Eyes Travelers Eye Relief"},{"form":"LIQUID","route":"OPHTHALMIC","productName":"Clear Eyes Triple Action"},{"form":"LIQUID","route":"OPHTHALMIC","productName":"Equate Eye Drops"},{"form":"LIQUID","route":"OPHTHALMIC","productName":"Advanced Relief"},{"form":"LIQUID","route":"OPHTHALMIC","productName":"Advanced relief"},{"form":"LIQUID","route":"OPHTHALMIC","productName":"CareOne Itchy Relief Eye Drops 15mL"},{"form":"LIQUID","route":"OPHTHALMIC","productName":"Colirio Ocusan"},{"form":"LIQUID","route":"OPHTHALMIC","productName":"Eyes Irritation Relief"},{"form":"LIQUID","route":"OPHTHALMIC","productName":"Leader Original Eye Drops"},{"form":"LIQUID","route":"OPHTHALMIC","productName":"Optimis7"},{"form":"LIQUID","route":"OPHTHALMIC","productName":"Redness reliever"},{"form":"LIQUID","route":"OPHTHALMIC","productName":"Redness reliever and Lubricant"},{"form":"LIQUID","route":"OPHTHALMIC","productName":"Rohto Digi-Eye"}]},"crossReferences":{"NUI":"N0000020740","MMSL":"5562","NDDF":"001803","UNII":"8P9X484T3F","VUID":"4022735","CHEBI":"CHEBI:28674","VANDF":"4018994","INN_ID":"519","RXNORM":"37935","UMLSCUI":"C0076286","chemblId":"CHEMBL1266","ChEMBL_ID":"CHEMBL1200413","KEGG_DRUG":"D00756","DRUGBANK_ID":"DB06764","PUBCHEM_CID":"5419","SNOMEDCT_US":"2183004","SECONDARY_CAS_RN":"118201-38-0","MESH_SUPPLEMENTAL_RECORD_UI":"C005810"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1979-","companyName":"Fougera Pharms","relationship":"Original Developer"}],"publicationCount":28,"therapeuticAreas":["Ophthalmology"],"atcClassification":{"source":"DrugCentral","atcCode":"R01AA06","allCodes":["R01AA06","R01AB03","S01GA02","S01GA52"]},"biosimilarFilings":[],"originalDeveloper":"Fougera Pharms","recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Fougera Pharms","companyId":"fougera-pharms","modality":"Small Molecule","firstApprovalDate":"1979","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1979-11-30T00:00:00.000Z","mah":"FOUGERA PHARMS","brand_name_local":null,"application_number":""},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1979-11-30T00:00:00.000Z","mah":"FOUGERA PHARMS","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1979-11-30T00:00:00.000Z","mah":"FOUGERA PHARMS","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1979-11-30T00:00:00.000Z","mah":"FOUGERA PHARMS","brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1979-11-30T00:00:00.000Z","mah":"FOUGERA PHARMS","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1979-11-30T00:00:00.000Z","mah":"FOUGERA PHARMS","brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:02:57.475211+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}